CUSIP: 67001K202
Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
14,118,109
-
Share change
-
-530,400
-
Total reported value
-
$99,245,657
-
Price per share
-
$7.03
-
Number of holders
-
64
-
Value change
-
-$6,822,472
-
Number of buys
-
26
-
Number of sells
-
25
Quarterly Holders Quick Answers
What is CUSIP 67001K202?
CUSIP 67001K202 identifies NVLNF - NOVELION THERAPEUTICS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2017
-
Previous quarter:
Q2 2017
Recent filing periods for CUSIP 67001K202:
Institutional Holders of NOVELION THERAPEUTICS INC - COM NEW (NVLNF) as of Q3 2017
As of 30 Sep 2017,
NOVELION THERAPEUTICS INC - COM NEW (NVLNF) was held by
64 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,118,109 shares.
The largest 10 holders included
Broadfin Capital, LLC, ARMISTICE CAPITAL, LLC, Stonepine Capital Management, LLC, MORGAN STANLEY, EdgePoint Investment Group Inc., Sarissa Capital Management LP, Healthcare Value Capital, LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, BlackRock Inc., and FMR LLC.
This page lists
64
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.